Key Opinion Leader Event :
Dysfunction or complete loss of function of the vestibular or cochlear system can induce vertigo, imbalance, tinnitus, hearing loss and leads to transient or permanent disability. Unfortunately there are no truly effective, approved and well tolerated treatments available for patients suffering from inner ear pathologies.
Founded in 2009, Sensorion is a French biopharmaceutical company dedicated to the development of targeted and innovative therapies to treat such disorders and fill the currently unmet medical needs.
The company is located in Montpellier (France). At the interface between academic research and industrial development, we adopt a multidisciplinary approach in collaboration with various partners in the ENT field (researchers, clinicians…) to develop new drugs.
Dear Madam, dear Sir, dear Shareholder,
As you may know, I was appointed CEO of SENSORION in April and I would like to take this opportunity to introduce myself and share a few words about this fantastic organization, which I am privileged to lead into the next stage of its development.
I began my career at Baxter where I held several positions (including roles in product development, operations and global marketing). My final role, at Baxter, was Vice President of the Global Hemophilia Franchise. After the Shire acquisition in 2016, I took charge of the Shire Global Genetic Diseases division, where I supervised all aspects of marketing, business and strategy for the rare genetic diseases portfolio.
I am really excited by what SENSORION can deliver for shareholders and patients. We are a clinical stage biotech company specialized in the treatment of the inner ear pathologies such as acute vertigo or hearing loss. There is an estimated $10B market size, which is mainly untapped as there are no targeted therapies approved for these indications.
Our ambition is to become the leader in our space by executing on our clinical pipeline. SENS-111, is currently in Phase II clinical testing for treatment of acute unilateral vestibulopathy. SENS-401, is completing a Phase I trial and has potential for treatment of lesions of the inner ear, such as sudden sensorineural hearing loss. And finally, we recently communicated positive preclinical results for the prevention of cisplatin induced ototoxicity after treatment with SENS-401.
The company has accomplished great things over the past 5 years and we are committed to building on this progress. We expect 2017 to be an important year for SENSORION as we progress our pipeline in clinical development.
I would like to thank you for your trust and support for SENSORION.
Nawal Ouzren, CEO